A novel mutation in the AVPR2 gene (222delA) associated with X-linked nephrogenic diabetes insipidus in a boy with growth failure

Endocr Pract. 2010 Mar-Apr;16(2):231-6. doi: 10.4158/EP09165.CR.

Abstract

Objective: To study the case of a 2 10/12-year-old boy who had growth failure and delayed bone maturation.

Methods: We reviewed the history, which revealed that he had had polyuria, polydipsia, lack of weight gain, and frequent vomiting since the age of 5 months. On physical examination, his height was 86 cm (-1.93 standard deviation [SD]), his weight 10.5 kg (-2.67 SD), and he had motor and mental retardation. His maternal great-grandfather also had polyuria and polydipsia (but not diabetes mellitus), suggesting X-linked nephrogenic diabetes insipidus as the underlying cause. The patient underwent a water deprivation-desmopressin test. The coding region of the AVPR2 gene was amplified by polymerase chain reaction and submitted to direct sequence analysis.

Results: The water deprivation test confirmed the diagnosis of diabetes insipidus, and administration of desmopressin did not diminish his water secretion. Direct sequencing of the AVPR2 gene revealed a novel deletion of adenine at position 222 (222delA) in exon 2. This mutation is predicted to lead to a frameshift beginning at amino acid 75 and a premature stop codon at position 115 (FS75>115X). His height and weight, as well as his motor skills, improved after initiation of therapy with hydrochlorothiazide and amiloride.

Conclusion: Growth delay can be associated with diabetes insipidus. The X-linked nephrogenic diabetes insipidus in this boy is caused by a novel mutation in the AVPR2 gene that is predicted to truncate the receptor protein.

Publication types

  • Case Reports

MeSH terms

  • Amiloride / therapeutic use
  • Child, Preschool
  • Diabetes Insipidus, Nephrogenic / drug therapy
  • Diabetes Insipidus, Nephrogenic / genetics*
  • Genetic Diseases, X-Linked / drug therapy
  • Genetic Diseases, X-Linked / genetics*
  • Humans
  • Hydrochlorothiazide / therapeutic use
  • Male
  • Mutation
  • Receptors, Vasopressin / genetics*
  • Sodium Channel Blockers / therapeutic use

Substances

  • Receptors, Vasopressin
  • Sodium Channel Blockers
  • Hydrochlorothiazide
  • Amiloride